Piterjiumlu Hastalarda Seruloplazmin, Albümin, İskemi-Modifiye Albümin ve Miyeloperoksidaz Düzeylerinin Belirlenmesi
Öz
Amaç: Biyobelirteçler
vücuttaki birçok hastalığın varlığının ya da ciddiyetinin ölçülebilir bir
göstergesidir. Öte yandan yapılan birçok klinik çalışmaya rağmen yaygın bir göz
hastalığı olan konjonktival piterjium etiyopatojenezi tam olarak
aydınlatılamamıştır. Fakat multifaktöriyel olduğu düşünülen etiyolojisinin bazı
biyobelirteçlerle olan sıkı ilişkisi de iyi bilinmektedir. Bu çalışmada
piterjium hastalığı ile serum seruloplazmin, albümin, iskemi-modifiye albümin
ve miyeloperoksidaz düzeyleri arasındaki ilişkinin incelenmesi amaçlanmıştır.
Gereç ve
Yöntemler:
Çalışmaya konjonktival piterjiumu olan 40 hasta ve yaş-cinsiyet uyumlu 40
sağlıklı gönüllü dahil edildi. Tüm olgulara detaylı oftalmolojik muayene
yapıldı. Ayrıca piterjium grubundaki olgularda piterjium derecelendirilmesi
yapıldı. Tüm olgulardan serum örnekleri toplandı ve seruloplazmin, albümin,
iskemi-modifiye albümin ve miyeloperoksidaz düzeylerine bakıldı. İstatistiksel
analizde Ki-kare testi, Bağımsız örneklemler t-testi, Mann-Whitney U testi ve
Spearman korelasyon analizi kullanıldı. P<0,05 düzeyi istatistiksel olarak
anlamlı kabul edildi.
Bulgular: Gruplar
demografik açıdan benzerdi. Gruplar arasında seruloplazmin, albümin,
iskemi-modifiye albümin ve miyeloperoksidaz düzeyleri açısından anlamlı fark
saptanmadı (sırasıyla P=0,762 P=0,572 P=0,202 ve P=0,176). Piterjium grubunda
korelasyon testinde albümin düzeyleri ile piterjium derecesi arasında negatif
ilişki olduğu görüldü (P=0,011).
Sonuç: Konjonktival
piterjium ile serum seruloplazmin, albümin, iskemi-modifiye albümin ve
miyeloperoksidaz düzeyleri arasında istatistiksel anlamlı bir ilişki
görülmemiştir. Bununla birlikte, albümin düzeyleri ile piterjium derecesi
arasındaki negatif ilişki geniş hasta gruplarıyla yapılacak ileri randomize
çalışmalara ihtiyaç olduğunu düşündürmektedir.
Anahtar Kelimeler
Kaynakça
- 1. Pierrakos C, Vincent JL. Sepsis biomarkers: a review. Crit Care. 2010; 14(1): R15. doi: 10.1186/cc8872.
- 2. Aronson JK, Ferner RE. Biomarkers-a general review. Curr Protoc Pharmacol. 2017; 76(1): 9.23.1-9.23.17. doi: 10.1002/cpph.19.
- 3. Liu CH, Abrams ND, Carrick DM, Chander P, Dwyer J, Hamlet MRJ, et al. Biomarkers of chronic inflammation in disease development and prevention: challenges and opportunities. Nat Immunol. 2017; 18(11): 1175-80. doi: 10.1038/ni.3828.
- 4. Arenas de Larriva AP, Alonso A, Norby FL, Roetker NS, Folsom AR. Circulating ceruloplasmin, ceruloplasmin-associated genes and the incidence of venous thromboembolism in the atherosclerosis risk in communities study. J Thromb Haemost. 2019; 17(5): 818-26. doi: 10.1111/jth.14420.
- 5. Mishra B, Pandey S, Niraula SR, Rai BK, Karki P, Baral N, et al. Utility of ischemia modified albumin as an early marker for diagnosis of acute coronary syndrome. J Nepal Health Res Counc. 2018; 16(1): 16-21.
- 6. Nauseef WM. Biosynthesis of human myeloperoxidase. Arch Biochem Biophys. 2018; 642: 1-9. doi: 10.1016/j.abb.2018.02.001.
- 7. Malozhen SA, Trufanov SV, Krakhmaleva DA. Pterygium: etiology, pathogenesis, treatment. Vestn Oftalmol. 2017; 133(5): 76-83. doi: 10.17116/oftalma2017133576-83.
- 8. John-Aryankalayil M, Dushku N, Jaworski CJ, Cox CA, Schultz G, Smith JA, et al. Microarray and protein analysis of human pterygium. Mol Vis. 2006; 12: 55-64.
- 9. Young AL, Cao D, Chu WK, Ng TK, Yip YWY, Jhanji V, et al. The evolving story of pterygium. Cornea. 2018; 37(Suppl 1): S55-S57. doi: 10.1097/ICO.0000000000001744.
- 10. Kanski JJ. Clinical ophthalmology. A systematic approach. 6th ed. Philadelphia, PA, Pennsylvania: Butterworth- Heinemann; 2007.
- 11. Wanzeler ACV, Barbosa IAF, Duarte B, Borges D, Barbosa EB, Kamiji D, et al. Mechanisms and biomarker candidates in pterygium development. Arq Bras Oftalmol. 2019; 82(6): 528-36. pii: S0004-27492019005013105. doi:10.5935/0004-2749.20190103.
- 12. Lluch S, Julio G, Pujol P, Merindano D. What biomarkers explain about pterygium OCT pattern. Graefes Arch Clin Exp Ophthalmol. 2016; 254(1): 143-8. doi: 10.1007/s00417-015-3186-9.
- 13. Tiong KI, Mohd Zahidin AZ, Sumugam SKA, Uchang J, Mohd Isa HD. Evaluation of interleukin-17 and interleukin-23 in pterygium: immunohistochemistry study. Asia Pac J Ophthalmol (Phila). 2017; 6(5): 403-6. doi: 10.22608/APO.2017134.
- 14. Josifovska N, Szabó DJ, Nagymihály R, Veréb Z, Facskó A, Eriksen K, et al. Cultivation and characterization of pterygium as an ex vivo study model for disease and therapy. Cont Lens Anterior Eye. 2017; 40(5): 283-92. doi: 10.1016/j.clae.2017.04.002.
- 15. Ljubojević V, Gajanin R, Amidzić L, Vujković Z. The expression and significance of p53 protein and Ki-67 protein in pterygium. Vojnosanit Pregl. 2016; 73(1): 16-20.
- 16. Livezeanu C, Crăiţoiu MM, Mănescu R, Mocanu C, Crăiţoiu S. Angiogenesis in the pathogenesis of pterygium. Rom J Morphol Embryol. 2011; 52(3): 837-44.
- 17. Perra MT, Maxia C, Zucca I, Piras F, Sirigu P. Immunohistochemical study of human pterygium. Histol Histopathol. 2002; 17(1): 139-49. doi:10.14670/HH-17.139.
Determination of Ceruloplasmin, Albumin, Ischemia-Modified Albumin and Myeloperoxidase Levels in Patients with Pterygium
Öz
Aim: Biomarkers are a measurable indicator of the presence or severity of
many diseases in the body. On the other hand, despite many clinical studies,
the etiopathogenesis of conjunctival pterygium which is a common eye disease
has not been fully clarified. However, it is well known that the etiology,
which is thought to be multifactorial, is closely related to some biomarkers.
In this study, we aimed to investigate the relationship between pterygium and
serum ceruloplasmin, albumin, ischemia-modified albumin and myeloperoxidase
levels.
Materials and Methods: Forty patients with conjunctival pterygium and 40 age
and sex-matched voluntary control subjects were included in the study. All
patients underwent detailed ophthalmological examination. Pterygium was graded
in pterygium group. Serum samples were obtained from all subjects and
ceruloplasmin, albumin, ischemia-modified albumin and myeloperoxidase levels
were determined. The statistical assessment was performed using Chi-square test,
Independent samples t-test, Mann-Whitney U test and Spearman’s correlation
analysis. P<0.05 was considered as statistically significant.
Results: The groups were similar in terms of
demographic parameters. There were no statistically significant difference
between groups with regards to the level of ceruloplasmin, albumin,
ischemia-modified albumin and myeloperoxidase (P=0.762 P=0.572 P=0.202 and
P=0.176 respectively). A negative correlation was found between albumin levels
and grade of pterygium in the pterygium group (P=0.011).
Conclusion: No statistically significant relationship
between conjunctival pterygium and serum ceruloplasmin, albumin,
ischemia-modified albumin and myeloperoxidase levels was observed. However, the
negative relationship between albumin levels and grade of pterygium suggests
that further randomized trials with large patient groups are needed.
Anahtar Kelimeler
Kaynakça
- 1. Pierrakos C, Vincent JL. Sepsis biomarkers: a review. Crit Care. 2010; 14(1): R15. doi: 10.1186/cc8872.
- 2. Aronson JK, Ferner RE. Biomarkers-a general review. Curr Protoc Pharmacol. 2017; 76(1): 9.23.1-9.23.17. doi: 10.1002/cpph.19.
- 3. Liu CH, Abrams ND, Carrick DM, Chander P, Dwyer J, Hamlet MRJ, et al. Biomarkers of chronic inflammation in disease development and prevention: challenges and opportunities. Nat Immunol. 2017; 18(11): 1175-80. doi: 10.1038/ni.3828.
- 4. Arenas de Larriva AP, Alonso A, Norby FL, Roetker NS, Folsom AR. Circulating ceruloplasmin, ceruloplasmin-associated genes and the incidence of venous thromboembolism in the atherosclerosis risk in communities study. J Thromb Haemost. 2019; 17(5): 818-26. doi: 10.1111/jth.14420.
- 5. Mishra B, Pandey S, Niraula SR, Rai BK, Karki P, Baral N, et al. Utility of ischemia modified albumin as an early marker for diagnosis of acute coronary syndrome. J Nepal Health Res Counc. 2018; 16(1): 16-21.
- 6. Nauseef WM. Biosynthesis of human myeloperoxidase. Arch Biochem Biophys. 2018; 642: 1-9. doi: 10.1016/j.abb.2018.02.001.
- 7. Malozhen SA, Trufanov SV, Krakhmaleva DA. Pterygium: etiology, pathogenesis, treatment. Vestn Oftalmol. 2017; 133(5): 76-83. doi: 10.17116/oftalma2017133576-83.
- 8. John-Aryankalayil M, Dushku N, Jaworski CJ, Cox CA, Schultz G, Smith JA, et al. Microarray and protein analysis of human pterygium. Mol Vis. 2006; 12: 55-64.
- 9. Young AL, Cao D, Chu WK, Ng TK, Yip YWY, Jhanji V, et al. The evolving story of pterygium. Cornea. 2018; 37(Suppl 1): S55-S57. doi: 10.1097/ICO.0000000000001744.
- 10. Kanski JJ. Clinical ophthalmology. A systematic approach. 6th ed. Philadelphia, PA, Pennsylvania: Butterworth- Heinemann; 2007.
- 11. Wanzeler ACV, Barbosa IAF, Duarte B, Borges D, Barbosa EB, Kamiji D, et al. Mechanisms and biomarker candidates in pterygium development. Arq Bras Oftalmol. 2019; 82(6): 528-36. pii: S0004-27492019005013105. doi:10.5935/0004-2749.20190103.
- 12. Lluch S, Julio G, Pujol P, Merindano D. What biomarkers explain about pterygium OCT pattern. Graefes Arch Clin Exp Ophthalmol. 2016; 254(1): 143-8. doi: 10.1007/s00417-015-3186-9.
- 13. Tiong KI, Mohd Zahidin AZ, Sumugam SKA, Uchang J, Mohd Isa HD. Evaluation of interleukin-17 and interleukin-23 in pterygium: immunohistochemistry study. Asia Pac J Ophthalmol (Phila). 2017; 6(5): 403-6. doi: 10.22608/APO.2017134.
- 14. Josifovska N, Szabó DJ, Nagymihály R, Veréb Z, Facskó A, Eriksen K, et al. Cultivation and characterization of pterygium as an ex vivo study model for disease and therapy. Cont Lens Anterior Eye. 2017; 40(5): 283-92. doi: 10.1016/j.clae.2017.04.002.
- 15. Ljubojević V, Gajanin R, Amidzić L, Vujković Z. The expression and significance of p53 protein and Ki-67 protein in pterygium. Vojnosanit Pregl. 2016; 73(1): 16-20.
- 16. Livezeanu C, Crăiţoiu MM, Mănescu R, Mocanu C, Crăiţoiu S. Angiogenesis in the pathogenesis of pterygium. Rom J Morphol Embryol. 2011; 52(3): 837-44.
- 17. Perra MT, Maxia C, Zucca I, Piras F, Sirigu P. Immunohistochemical study of human pterygium. Histol Histopathol. 2002; 17(1): 139-49. doi:10.14670/HH-17.139.
Ayrıntılar
| Birincil Dil | Türkçe |
|---|---|
| Konular | Sağlık Kurumları Yönetimi |
| Bölüm | Araştırma Makaleleri |
| Yazarlar | |
| Yayımlanma Tarihi | 31 Ocak 2020 |
| Gönderilme Tarihi | 1 Kasım 2019 |
| Yayımlandığı Sayı | Yıl 2020 Cilt: 10 Sayı: 1 |
